Literature DB >> 4129562

A dose response evaluation of delta-1-testololactone in advanced breast cancer.

H Volk, R H Deupree, I S Goldenberg, R C Wilde, R A Carabasi, G C Escher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4129562     DOI： 10.1002/1097-0142(197401)33:1<9::aid-cncr2820330104>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  7 in total

Review 1.  Anti-estrogens and aromatase inhibitors: tamoxifen and testolactone.

Authors:  F Sciarra
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

Review 2.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 4.  First generation aromatase inhibitors--aminoglutethimide and testololactone.

Authors:  G Cocconi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.

Authors:  P E Lønning; S Kvinnsland; T Thorsen; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

6.  Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.

Authors:  P E Lønning
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Aromatase inhibitors in malignant diseases of aging.

Authors:  D C Johannessen; P E Lønning
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.